Stockscreener 앱 받기
192.86
0.05%
0.10
시장 영업 전:
192.39
-0.47
-0.24%
전일 마감가:
$192.76
열려 있는:
$191.56
하루 거래량:
1.87M
Relative Volume:
0.83
시가총액:
$41.34B
수익:
$742.00K
순이익/손실:
$-1.37B
주가수익비율:
-27.27
EPS:
-7.0731
순현금흐름:
$-1.07B
1주 성능:
-5.86%
1개월 성능:
-7.93%
6개월 성능:
+101.36%
1년 성능:
+334.27%
1일 변동 폭
$191.22
$195.28
1주일 범위
$188.18
$205.15
52주 변동 폭
$42.18
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
192.86 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-02-27 | 재개 | UBS | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing? - Yahoo Finance
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - markets.businessinsider.com
Form 4 Revolution Medicines Inc For: 22 September By Investing.com - Investing.com Canada
Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE - Yahoo Finance
Revolution Medicines (NASDAQ: RVMD) director plans stock sale from option exercise - Stock Titan
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today - benzinga.com
Illinois grew the science behind a breakthrough cancer drug — but couldn’t hold onto the company - chicagobusiness.com
RVMD Maintained by B of A Securities -- Price Target Raised to $265 - gurufocus.com
Client Revolution Medicines Secures 672,000-Square-Foot Redwood City Lease in former Google Space - Procopio
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Promising 31.56% Upside in the Precision Oncology Space - DirectorsTalk Interviews
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to FTSE All-World Index - marketscreener.com
This Insider Has Just Sold Shares In Revolution Medicines - simplywall.st
Revolution Medicines chief development officer sells $67,940 in stock By Investing.com - Investing.com South Africa
Revolution Medicines officer sells $353,449 in shares By Investing.com - Investing.com Nigeria
Revolution Medicines’ senior advisor sells $1.1m in stock By Investing.com - Investing.com South Africa
Revolution Medicines CEO Mark Goldsmith sells $2.78m in stock - Investing.com
Revolution Medicines’ Jeff Cislini sells $670k in common stock - Investing.com
Revolution Medicines COO Margaret Horn sells $989,612 of common stock By Investing.com - Investing.com Nigeria
Revolution Medicines CFO Jack Anders sells $807,513 in stock - Investing.com
Revolution Medicines (RVMD) exec sells 1,774 shares, keeps 39,575 RSUs - Stock Titan
Revolution Medicines (RVMD) legal chief makes pre-set stock sale for taxes - Stock Titan
Revolution Medicines (RVMD) insider adds new sale after multimillion-dollar trades - Stock Titan
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? - The Globe and Mail
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift - Yahoo Finance
Officer at Revolution Medicines (RVMD) plans 331-share sale - Stock Titan
Revolution Medicines officer plans $484K sale | RVMD SEC FilingForm 144 - Stock Titan
After $18.7M stock sale, Revolution Medicines (RVMD) officer files notice for another RSU share sale - Stock Titan
Officer at Revolution Medicines (NASDAQ: RVMD) plans 4,830-share stock sale after RSU vesting - Stock Titan
Over $16M in recent stock sales as Revolution Medicines (NASDAQ: RVMD) filer Mark A. Goldsmith plans another trade - Stock Titan
Revolution Medicines (RVMD) officer lines up another stock sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) insider plans sale of 3,939 shares - Stock Titan
Revolution Medicines to anchor former Google campus as Silicon Valley office market shifts - bizjournals.com
A pancreatic cancer drug gets FDA breakthrough status. Its combo is still being tested. - Stock Titan
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Promising 23.28% Upside in the Biotech Sector - DirectorsTalk Interviews
Revolution Medicines (RVMD) exec exercises options, sells stock - Stock Titan
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs - Yahoo Finance
Abu Dhabi Investment Council Co P.J.S.C's Revolution Medicines Inc(RVMD) Holding History - GuruFocus
Revolution Medicines (NASDAQ: RVMD) officer plans multi-million stock option share sale - Stock Titan
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Revolution Medicines director Lorence Kim sells $3.58m in stock - investing.com
Revolution Medicines Director Lorence H. Kim Sells 14,090 Shares via Revocable Trust Under 10b5-1 Plan - Kalkine Media
Planned multimillion stock sale at Revolution Medicines (RVMD) - Stock Titan
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More. - Barron's
RVMD - Finviz
Morgan Stanley Initiates Overweight on RVMD, Highlighting RAS Pi - GuruFocus
Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise - Seeking Alpha
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Revolution Medicines Inc 주식 (RVMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mancini Anthony | See Remarks |
Sep 16 '26 |
Sale |
199.24 |
1,774 |
353,449 |
42,116 |
| Kelsey Stephen Michael | See Remarks |
Sep 16 '26 |
Sale |
199.24 |
5,569 |
1,109,554 |
286,307 |
| Horn Margaret A | Chief Operating Officer |
Sep 16 '26 |
Sale |
199.24 |
4,967 |
989,613 |
149,680 |
| GOLDSMITH MARK A | See Remarks |
Sep 16 '26 |
Sale |
199.24 |
13,988 |
2,786,938 |
253,342 |
| Cislini Jeff | SVP & General Counsel |
Sep 16 '26 |
Sale |
199.24 |
3,366 |
670,631 |
52,541 |
| Anders Jack | Chief Financial Officer |
Sep 16 '26 |
Sale |
199.24 |
4,053 |
807,513 |
119,216 |
0.66%
1.97%
자본화:
|
볼륨(24시간):